GlucoTrack, Inc. (GCTK)
USD 0.23
(-5.78%)
USD 0.23
(-5.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.09 Million USD | -60.83% |
| 2022 | -4.4 Million USD | -13.63% |
| 2021 | -3.99 Million USD | -25.77% |
| 2020 | -3.08 Million USD | 10.9% |
| 2019 | -3.45 Million USD | 46.56% |
| 2018 | -6.63 Million USD | 38.36% |
| 2017 | -10.23 Million USD | -87.84% |
| 2016 | -5.33 Million USD | 5.03% |
| 2015 | -5.78 Million USD | -64.93% |
| 2014 | -3.57 Million USD | -19.32% |
| 2013 | -2.99 Million USD | -9.27% |
| 2012 | -2.73 Million USD | -18.6% |
| 2011 | -2.3 Million USD | -68.46% |
| 2010 | -2.5 Million USD | -17.19% |
| 2009 | -1.17 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.48 Million USD | -51.95% |
| 2024 Q1 | -2.94 Million USD | -22.26% |
| 2023 Q1 | -1.28 Million USD | 0.23% |
| 2023 Q4 | -2.42 Million USD | -209.09% |
| 2023 FY | - USD | -60.83% |
| 2023 Q3 | 2.22 Million USD | 289.03% |
| 2023 Q2 | -1.17 Million USD | 8.13% |
| 2022 Q1 | -1.08 Million USD | 24.51% |
| 2022 Q4 | -1.28 Million USD | -38.85% |
| 2022 Q3 | -924 Thousand USD | 17.35% |
| 2022 FY | - USD | -13.63% |
| 2022 Q2 | -1.11 Million USD | -3.14% |
| 2021 FY | - USD | -25.77% |
| 2021 Q2 | -863 Thousand USD | 2.38% |
| 2021 Q3 | -756 Thousand USD | 12.4% |
| 2021 Q4 | -1.43 Million USD | -89.95% |
| 2021 Q1 | -884 Thousand USD | -2.03% |
| 2020 Q4 | -866.38 Thousand USD | 1.23% |
| 2020 Q2 | -593.6 Thousand USD | 20.14% |
| 2020 Q1 | -743.29 Thousand USD | -24.86% |
| 2020 Q3 | -877.22 Thousand USD | -47.78% |
| 2020 FY | - USD | 10.9% |
| 2019 Q4 | -595.3 Thousand USD | 38.65% |
| 2019 Q2 | -881.57 Thousand USD | 12.89% |
| 2019 Q3 | -970.31 Thousand USD | -10.07% |
| 2019 Q1 | -1.01 Million USD | 0.03% |
| 2019 FY | - USD | 46.56% |
| 2018 Q3 | -1.61 Million USD | 19.67% |
| 2018 FY | - USD | 38.36% |
| 2018 Q4 | -1.01 Million USD | 37.2% |
| 2018 Q2 | -2 Million USD | -2.49% |
| 2018 Q1 | -1.95 Million USD | 26.53% |
| 2017 FY | - USD | -87.84% |
| 2017 Q4 | -2.66 Million USD | -1.27% |
| 2017 Q1 | -2.49 Million USD | -91.63% |
| 2017 Q2 | -2.63 Million USD | -5.41% |
| 2017 Q3 | -2.63 Million USD | 0.06% |
| 2016 Q1 | -1.21 Million USD | 20.42% |
| 2016 Q2 | -1.56 Million USD | -29.19% |
| 2016 FY | - USD | 5.03% |
| 2016 Q4 | -1.3 Million USD | 11.52% |
| 2016 Q3 | -1.47 Million USD | 5.97% |
| 2015 Q1 | -1.52 Million USD | -52.54% |
| 2015 Q3 | -1.08 Million USD | 0.26% |
| 2015 Q4 | -1.52 Million USD | -40.59% |
| 2015 Q2 | -1.08 Million USD | 28.66% |
| 2015 FY | - USD | -64.93% |
| 2014 Q4 | -998.56 Thousand USD | -21.6% |
| 2014 Q3 | -821.21 Thousand USD | 6.02% |
| 2014 Q2 | -873.81 Thousand USD | 0.6% |
| 2014 Q1 | -879.09 Thousand USD | 88.31% |
| 2014 FY | - USD | -19.32% |
| 2013 Q3 | -718.65 Thousand USD | 12.79% |
| 2013 Q4 | -7.52 Million USD | -946.67% |
| 2013 FY | - USD | -9.27% |
| 2013 Q1 | -680.79 Thousand USD | -1.49% |
| 2013 Q2 | -824.09 Thousand USD | -21.05% |
| 2012 Q2 | -747.83 Thousand USD | -16.57% |
| 2012 Q1 | -641.5 Thousand USD | -8.55% |
| 2012 FY | - USD | -18.6% |
| 2012 Q4 | -670.82 Thousand USD | 1.35% |
| 2012 Q3 | -679.99 Thousand USD | 9.07% |
| 2011 Q2 | -490.62 Thousand USD | 8.26% |
| 2011 Q4 | -590.99 Thousand USD | 14.84% |
| 2011 Q3 | -693.95 Thousand USD | -41.44% |
| 2011 Q1 | -534.82 Thousand USD | 0.0% |
| 2011 FY | - USD | -68.46% |
| 2010 FY | - USD | -17.19% |
| 2009 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 84.46% |
| AngioDynamics, Inc. | -14.29 Million USD | 50.385% |
| AtriCure, Inc. | -8.1 Million USD | 12.554% |
| Avinger, Inc. | -16.34 Million USD | 56.619% |
| Azenta, Inc. | 55.15 Million USD | 112.857% |
| BioLife Solutions, Inc. | -45.23 Million USD | 84.325% |
| The Cooper Companies, Inc. | 882.8 Million USD | 100.803% |
| Daxor Corporation | 329.74 Thousand USD | 2250.482% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 46.272% |
| Femasys Inc. | -13.16 Million USD | 46.156% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 174.697% |
| Hologic, Inc. | 1.29 Billion USD | 100.547% |
| ICU Medical, Inc. | 307.69 Million USD | 102.305% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.296% |
| KORU Medical Systems, Inc. | -9.39 Million USD | 24.561% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 114.474% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -7.846% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -7.846% |
| Masimo Corporation | 236.7 Million USD | 102.996% |
| Microbot Medical Inc. | -10.63 Million USD | 33.318% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 144.964% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 103.064% |
| Nephros, Inc. | -1.37 Million USD | -414.213% |
| NovoCure Limited | -175.86 Million USD | 95.968% |
| NEXGEL, Inc. | -2.73 Million USD | -159.744% |
| NEXGEL, Inc. | -2.73 Million USD | -159.744% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 91.802% |
| OraSure Technologies, Inc. | 76.15 Million USD | 109.311% |
| Pro-Dex, Inc. | 8.33 Million USD | 185.095% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 83.263% |
| Predictive Oncology Inc. | -13.18 Million USD | 46.207% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -182.291% |
| QuidelOrtho Corporation | 545.6 Million USD | 101.3% |
| Repligen Corporation | 124.29 Million USD | 105.705% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -2352.81% |
| STAAR Surgical Company | 33.22 Million USD | 121.345% |
| Sharps Technology, Inc. | -8.98 Million USD | 21.039% |
| Utah Medical Products, Inc. | 24.8 Million USD | 128.587% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 103.056% |
| Jin Medical International Ltd. | 3.44 Million USD | 305.961% |